Procter & Gamble to Acquire Supplements Maker Thorne, Expanding Health Portfolio

Procter & Gamble has confirmed it will acquire supplements maker Thorne, a strategic move to bolster the consumer goods giant's position in the health and wellness sector. The deal was announced by P&G CEO Shailesh Jejurikar in a Tuesday interview with CNBC.

Deal Terms

While the specific financial terms of the acquisition were not disclosed, Jejurikar characterized the valuation as appropriate for the company's performance.

"What I can say is the price is a good price for the growth rates they have," Jejurikar told CNBC. "It’s kind of in line with the industry benchmarks we’ve seen." As of the announcement, neither P&G nor Thorne had provided additional details on the transaction, according to Reuters.

Strategic Rationale

Ad

The acquisition comes as P&G seeks new avenues for growth. The company recently forecast slower annual sales growth, even as its beauty and wellness division has posted strong results. This suggests continued consumer willingness to spend on discretionary self-care products, a trend that the Thorne acquisition directly taps into.

Market Context

The deal follows earlier reports of a potential sale of Thorne. In June, Reuters reported that UK-based consumer health company Haleon was also a bidder for the supplements maker. A separate Financial Times report from June valued Thorne at up to $4 billion, providing a benchmark for the scale of the transaction.